Suparna Thakali

Combined ctDNA and serum PSA for dynamic monitoring of metastatic prostate cancer starting first-line treatment: a prospective national cohort study

Anuradha Jayaram, Memuna Rashid, Alison H. M. Reid, Francesco Orlando et autres

The prognosis of newly diagnosed metastatic prostate cancer is highly variable. The primary objective of the PARADIGM prospective cohort study was to evaluate predictors of survival in blood collected at the start of each of the first six treatment cycles from 114 …

gb, it (code pays fourni par la source)

External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol

Charles Parker, Larissa Mendes, Vinnie Y.T. Liu, Emily Grist et autres

BACKGROUND: Effective prognostication improves selection of patients with prostate cancer for treatment combinations. We aimed to evaluate whether a previously developed multimodal artificial intelligence (MMAI) algorithm was prognostic in very advanced prostate cancer using data from four phase 3 trials of the …

gb, us, ch (code pays fourni par la source)

Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer

Gianmarco Leone, Francesco Orlando, Peter Dutey‐Magni, Osvaldas Vainauskas et autres

This randomized clinical trial explores whether hormone intensification at start of androgen deprivation therapy alters selection of androgen receptor (AR) gene alterations within the gene body and/or enhancer region.

gb, it (code pays fourni par la source)

Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial

Maria Ruiz-Vico, Daniel Wetterskog, Francesco Orlando, Suparna Thakali et autres

BACKGROUND AND OBJECTIVE: The PRESIDE (NCT02288247) randomized trial demonstrated prolonged progression-free survival (PFS) with continuing enzalutamide beyond progression in metastatic castration-resistant prostate cancer (mCRPC) patients starting docetaxel. This study aims to test the associations of PFS and circulating tumor DNA (ctDNA) prior …

gb, es, it, se, ru, tr, de, pl, us (code pays fourni par la source)

Abstract 973: Plasma androgen receptor (AR) copy number gain at progression in patients randomized in the STAMPEDE phase 3 abiraterone acetate, prednisolone (AAP) and enzalutamide (ENZ) trial: An ancillary biomarker study

Gianmarco Leone, Francesco Orlando, Suparna Thakali, Sharanpreet Lall et autres

Abstract Addition of ENZ or AAP to androgen deprivation therapy (ADT) as first-line treatment for advanced prostate cancer improves survival compared to ADT alone. Genomic alterations in AR associate with resistance to ENZ/AAP when started for castration-resistant prostate cancer (CRPC). We aimed …

gb, it (code pays fourni par la source)

1836P Blood based biomarkers identify metastatic castration-resistant prostate cancer (mCRPC) with the greatest benefit from continuing enzalutamide (ENZ) beyond progression in combination with docetaxel (Doc): A pre-specified biomarker study of the phase IIIb PRESIDE trial

M. Ruiz Vico, Daniel Wetterskog, Suparna Thakali, Francesco Orlando et autres

gb, es, it, us, se, ru, tr, pl, de (code pays fourni par la source)

Nickel partitioning in acid soils at low moisture content

Alexander A. Ponizovsky, Suparna Thakali, Herbert E. Allen, Dominic M. Di Toro et autres

ru, us (code pays fourni par la source)

Developing a TBLM: copper effect on barley root elongation

Suparna Thakali, Herbert E. Allen, Darquea Toro, Alexander A. Ponizovsky et autres

Terrestrial Biotic Ligand Model (TBLM) to predict copper toxicity in soil systems

Suparna Thakali, Alexander A. Ponizovsky, David M. Metzler, Henry T. Allen et autres